CARISOPRODOL AND ASPIRIN Drug Patent Profile

Which patents cover Carisoprodol And Aspirin, and when can generic versions of Carisoprodol And Aspirin launch?

Carisoprodol And Aspirin is a drug marketed by Chartwell Rx, Genus, Novast Labs, and Oxford Pharms. and is included in four NDAs.

The generic ingredient in CARISOPRODOL AND ASPIRIN is aspirin; carisoprodol. There are twenty-two drug master file entries for this compound. Additional details are available on the aspirin; carisoprodol profile page.

Summary for CARISOPRODOL AND ASPIRIN

US Patents:	0
Applicants:	4
NDAs:	4

US Patents and Regulatory Information for CARISOPRODOL AND ASPIRIN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Chartwell Rx	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	089594-001	Mar 31, 1989		DISCN	No	No
Oxford Pharms	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040252-001	Dec 10, 1997		DISCN	No	No
Genus	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040116-001	Apr 25, 1996		DISCN	No	No
Novast Labs	CARISOPRODOL AND ASPIRIN	aspirin; carisoprodol	TABLET;ORAL	040832-001	Jan 7, 2010		DISCN	No	No

CARISOPRODOL AND ASPIRIN: DIVERSIFIED THERAPEUTIC IP AND MARKET DYNAMICS

Last updated: February 19, 2026

This analysis evaluates the investment landscape for Carisoprodol and Aspirin, focusing on patent status, market exclusivity, and therapeutic applications. Carisoprodol, primarily a skeletal muscle relaxant, and Aspirin, a widely used analgesic, anti-inflammatory, and antithrombotic agent, present distinct patent profiles and market penetration. Understanding their intellectual property (IP) protection, generic competition, and potential for novel formulations or combination therapies is crucial for assessing investment viability.

WHAT IS THE CURRENT PATENT LANDSCAPE FOR CARISOPRODOL AND ASPIRIN?

Carisoprodol Patent Status

Carisoprodol, originally developed by Wallace Laboratories and marketed as Soma, has long been off-patent in its original formulation. The compound was first patented in the 1950s. U.S. Patent No. 2,737,467, related to Carisoprodol and its synthesis, expired decades ago. Consequently, generic versions of Carisoprodol have been available for many years, leading to significant price erosion and limited opportunities for direct patent enforcement on the base molecule.

The primary IP considerations for Carisoprodol now lie in potential new uses, novel formulations (e.g., extended-release, combination products), or specific manufacturing processes that might be eligible for new patent protection. However, the age of the compound and its widespread generic availability present substantial challenges for securing market exclusivity through novel IP.

Aspirin Patent Status

Aspirin (acetylsalicylic acid) has a patent history dating back to its synthesis and patenting by Felix Hoffmann at Bayer in 1897. All original patents protecting Aspirin have long since expired. Like Carisoprodol, Aspirin is a widely available generic medication. Its extensive therapeutic applications, from pain relief to cardiovascular disease prevention, are well-established.

Investment opportunities related to Aspirin are not centered on protecting the base molecule. Instead, they focus on:

• New Indications: Discovering and patenting novel therapeutic uses for Aspirin.
• Novel Formulations: Developing and patenting improved delivery systems or dosage forms, such as enteric-coated tablets, chewable formulations, or combination products with other active pharmaceutical ingredients (APIs).
• Combination Therapies: Patenting specific combinations of Aspirin with other drugs for synergistic effects or to target specific disease pathways. For example, low-dose Aspirin in combination with anticoagulants for stroke prevention.

Recent patent filings often pertain to these secondary innovations rather than the molecule itself. The challenge is to demonstrate clear novelty, non-obviousness, and utility to secure new patent rights in a crowded therapeutic space.

WHAT ARE THE KEY MARKET EXCLUSIVITY FACTORS FOR THESE DRUGS?

Carisoprodol Market Exclusivity

The market exclusivity for Carisoprodol has largely been eroded due to its generic status.

• Generic Competition: Numerous pharmaceutical companies manufacture and market generic Carisoprodol. This intense competition drives down prices and limits the profitability of generic manufacturers.
• Regulatory Status: Carisoprodol is classified as a Schedule IV controlled substance in the United States by the Drug Enforcement Administration (DEA) due to its potential for abuse and dependence. This regulatory status, while not a patent-driven exclusivity, impacts its distribution, prescribing, and marketing. It can create barriers to entry for new manufacturers but does not confer market exclusivity in the traditional sense.
• Limited New IP: As discussed, the lack of significant new patentable innovations for Carisoprodol means that companies cannot rely on patent protection to secure extended market exclusivity.

The market for Carisoprodol is mature and driven by cost-effectiveness and accessibility. Companies involved in this market typically operate on high-volume, low-margin models.

Aspirin Market Exclusivity

Aspirin's market exclusivity is also primarily defined by its generic status, but its broad therapeutic reach and established role in preventive medicine present unique dynamics.

• Generic Availability: Aspirin is one of the most ubiquitous medications globally, available in countless generic formulations.
• Over-the-Counter (OTC) Status: Low-dose Aspirin for cardiovascular prevention and higher doses for pain relief are widely available OTC in many markets, further diminishing any brand-driven exclusivity.
• Brand Loyalty and Recognition: While generic competition is dominant, some branded Aspirin products (e.g., Bayer Aspirin) retain strong brand recognition and consumer loyalty, particularly for specific indications like heart health. This brand equity can translate to a small market share advantage but does not equate to patent-protected exclusivity.
• Focus on Combination Products: Market exclusivity for newer Aspirin-related products often comes from patenting specific combination therapies. For instance, combining Aspirin with another antiplatelet agent or an anticoagulant, where the specific synergistic effect or improved patient outcome is patented.

The investment attractiveness of Aspirin lies less in protecting the molecule and more in innovative delivery systems or combination therapies that can carve out new market niches or offer demonstrable clinical advantages.

WHAT ARE THE PRIMARY THERAPEUTIC APPLICATIONS AND TARGET PATIENT POPULATIONS?

Carisoprodol Therapeutic Applications

Carisoprodol is primarily indicated for the short-term relief of discomfort associated with acute, painful musculoskeletal conditions.

• Primary Indication: Relief of muscle spasms and associated pain.
• Target Patient Population: Adults experiencing acute muscle strains, sprains, or other painful musculoskeletal injuries.
• Mechanism of Action: The exact mechanism of Carisoprodol is not fully understood. It is believed to exert its effects through central nervous system depression. It is metabolized in the liver, and its active metabolite, meprobamate, has anxiolytic and sedative properties and is also a controlled substance.
• Duration of Use: Typically recommended for short-term use, generally not exceeding two to three weeks. Prolonged use is associated with a higher risk of dependence.

The narrow therapeutic window and potential for abuse limit its application and have led to regulatory scrutiny and some market withdrawal in certain regions.

Aspirin Therapeutic Applications

Aspirin possesses a broad spectrum of therapeutic applications, making it a cornerstone medication.

• Analgesic: Relief of mild to moderate pain, including headaches, muscle aches, dental pain, and menstrual cramps.
• Anti-inflammatory: Reduction of inflammation associated with conditions like arthritis, although stronger NSAIDs are often preferred for severe inflammatory conditions.
• Antipyretic: Reduction of fever.
• Antiplatelet (Antithrombotic): Low-dose Aspirin is a critical therapy for the prevention of cardiovascular events such as heart attack and stroke in patients with established cardiovascular disease or at high risk. It inhibits platelet aggregation by irreversibly blocking cyclooxygenase (COX) enzymes.
• Target Patient Populations:
  • Individuals experiencing acute pain and fever.
  • Patients with inflammatory conditions (e.g., rheumatoid arthritis).
  • Individuals requiring primary or secondary prevention of thrombotic events (e.g., patients with a history of myocardial infarction or stroke, those undergoing certain cardiac procedures).
  • Individuals with specific conditions like preeclampsia during pregnancy (under strict medical supervision).

The versatility of Aspirin's applications contributes to its sustained market presence and ongoing research into new uses and combinations.

WHAT ARE THE POTENTIAL FOR REPOSITIONING AND NOVEL FORMULATIONS?

Carisoprodol Repositioning and Formulation Potential

The potential for significant repositioning or novel formulation of Carisoprodol is limited due to its existing profile and regulatory concerns.

• Repositioning Challenges:
  • Abuse Potential: The Schedule IV classification in the U.S. and similar controls elsewhere present substantial regulatory hurdles for any new indication that might increase exposure or encourage off-label use.
  • Limited Efficacy Beyond Musculoskeletal Pain: There is little evidence to suggest efficacy in other major therapeutic areas.
  • Availability of Safer Alternatives: For pain management, numerous other analgesics and muscle relaxants with better safety profiles are available.
• Novel Formulation Opportunities (Limited):
  • Controlled-Release Formulations: While theoretically possible, developing a controlled-release version might not significantly enhance its therapeutic benefit for acute muscle spasms, which require rapid onset of action. It could also potentially exacerbate abuse risks if sustained drug levels are maintained.
  • Combination Products: Combining Carisoprodol with a non-narcotic analgesic (e.g., acetaminophen or ibuprofen) has been explored and exists in the market. However, such combinations do not typically confer new patent protection on Carisoprodol itself, and the market penetration is modest due to the limited duration of therapy.
  • Specific Manufacturing Processes: Patents could potentially be filed for novel, more efficient, or environmentally friendly synthesis pathways, but these are process patents and do not grant market exclusivity for the drug itself.

The focus for Carisoprodol would likely be on optimizing its existing use within its current therapeutic niche, with any patent activity being highly specific and incremental.

Aspirin Repositioning and Formulation Potential

Aspirin offers substantial potential for repositioning and the development of novel formulations, driven by its extensive safety data and established efficacy.

• Repositioning Opportunities:
  • Oncology: Significant research is ongoing regarding Aspirin's role in cancer prevention and treatment, particularly for colorectal cancer and potentially other solid tumors. Patents could be sought for specific regimens or patient populations responding favorably to Aspirin therapy in oncological settings. ([1])
  • Neurodegenerative Diseases: Emerging research suggests Aspirin may have a role in slowing the progression of neurodegenerative conditions like Alzheimer's and Parkinson's disease, potentially through its anti-inflammatory and anti-amyloid properties.
  • Other Inflammatory Conditions: While not a primary anti-inflammatory for severe conditions, its anti-inflammatory effects could be leveraged in other chronic inflammatory processes.
• Novel Formulation Opportunities:
  • Enhanced Bioavailability: Developing formulations that improve Aspirin's absorption or reduce gastrointestinal (GI) side effects. This includes:
    • Enteric-Coated Tablets: Widely available, but further improvements in coating technology could reduce GI irritation more effectively.
    • Lysine Aspirin Formulations: Salts of Aspirin, like Aspirin lysine, are designed for faster absorption and may offer improved tolerability. ([2])
    • Nanoparticle Formulations: Encapsulating Aspirin in nanoparticles could improve solubility, bioavailability, and targeted delivery, potentially reducing systemic side effects.
  • Combination Therapies: This is a major area for innovation.
    • Cardiovascular Combinations: Fixed-dose combinations of Aspirin with other antiplatelets (e.g., clopidogrel, ticagrelor), anticoagulants (e.g., novel oral anticoagulants), or statins for comprehensive cardiovascular risk management. Patents would cover the specific synergistic effects and fixed-dose ratios.
    • Pain Management Combinations: Combining Aspirin with other analgesics (e.g., opioids, other NSAIDs) or adjuvant therapies for enhanced pain relief or to mitigate side effects.
  • Controlled-Release Formulations: While low-dose Aspirin is often taken daily, controlled-release formulations could potentially optimize its therapeutic index, particularly in areas like chronic inflammation or cancer prevention, by maintaining steady plasma concentrations and minimizing peak-dose GI toxicity.

The patent strategy for Aspirin revolves around identifying novel applications or optimizing its delivery and combination with other agents to create a differentiated product with extended market exclusivity.

WHAT ARE THE KEY COMPETITIVE CHALLENGES AND MARKET DYNAMICS?

Carisoprodol Competitive Landscape

The competitive landscape for Carisoprodol is characterized by saturation and price sensitivity.

• Generic Manufacturers: The market is dominated by multiple generic manufacturers, leading to intense price competition. Profit margins are slim, and market share is often gained through cost-efficiency and distribution networks.
• Regulatory Scrutiny: The DEA's classification as a Schedule IV controlled substance imposes stricter regulatory oversight, impacting manufacturing, distribution, and prescribing patterns. This can act as a barrier to entry for new players who are not equipped to handle these requirements.
• Limited Differentiation: With no patent protection on the base molecule, differentiation is primarily based on price, availability, and packaging. There is little scope for therapeutic differentiation.
• Prescriber Behavior: Physicians are increasingly cautious about prescribing Carisoprodol due to its abuse potential and the availability of alternatives. This limits the overall demand.
• Formulation Competition: Existing combination products (e.g., Carisoprodol/Acetaminophen) compete with single-ingredient products and other analgesic/muscle relaxant combinations.

Aspirin Competitive Landscape

Aspirin's competitive landscape is vast and multifaceted, spanning prescription, OTC, and specialized formulations.

• Major Pharmaceutical Companies: Brands like Bayer maintain significant market share through brand recognition and established distribution channels.
• Generic Manufacturers: Thousands of generic manufacturers produce Aspirin globally, ensuring widespread availability and low cost.
• OTC Market Dominance: The majority of Aspirin sales are in the OTC segment, driven by its use for pain, fever, and cardiovascular prevention.
• Specialty Formulations: Companies developing novel formulations or combination products (e.g., enhanced GI tolerability, specific cardiovascular combinations) compete in higher-value segments. Patents are critical for defending these niches.
• Therapeutic Alternatives: Aspirin competes with a wide array of other analgesics (acetaminophen, ibuprofen, naproxen, opioids), anti-inflammatories, and antithrombotics. The choice of therapy depends on the indication, patient profile, and risk-benefit assessment.
• Public Health Initiatives: Aspirin's role in public health campaigns for cardiovascular disease prevention influences its market demand and accessibility.

The competitive dynamics for Aspirin are driven by a combination of broad accessibility, established therapeutic value, and ongoing innovation in specific applications and delivery methods.

WHAT ARE THE INVESTMENT IMPLICATIONS AND STRATEGIES?

Carisoprodol Investment Implications

Investing in Carisoprodol-related assets presents challenges due to its mature market and limited IP runway.

• Low Growth Potential: The market for Carisoprodol is largely stagnant or declining due to regulatory pressures and the availability of alternatives. Significant growth is unlikely.
• Price Erosion: Intense generic competition ensures continued downward pressure on prices, impacting profitability for manufacturers.
• Regulatory Risk: Ongoing scrutiny regarding abuse potential could lead to further restrictions, impacting market access and demand.
• Limited Scope for IP-Driven Returns: Opportunities for acquiring or developing patent-protected assets are scarce. Existing patents are expired, and new patentable inventions are difficult to secure and defend in this space.
• Focus on Manufacturing Efficiency: Investments are likely to be in companies with highly efficient manufacturing processes and robust distribution networks to compete on cost.
• Niche Combination Products: Potential exists in developing or acquiring companies with established, albeit modest, market share in specific Carisoprodol combination products, but this does not offer substantial upside.

Recommendation: Investments in Carisoprodol are generally not recommended for significant growth-oriented strategies. Any investment would likely be in the context of a diversified portfolio of mature generics, focusing on operational efficiency rather than R&D or IP acquisition.

Aspirin Investment Implications

Investing in Aspirin offers diverse opportunities, particularly in areas of novel formulations and repositioning.

• Established Market with Growth Pockets: While the base Aspirin market is mature, specific segments like cardiovascular prevention and emerging indications offer growth potential.
• IP-Driven Opportunities: The primary investment attractive lies in companies developing and patenting:
  • Novel Formulations: Improving efficacy, tolerability, or convenience.
  • Combination Therapies: Creating synergistic products for cardiovascular, oncological, or other indications.
  • New Indications: Successfully navigating clinical trials and obtaining regulatory approval for repositioned uses (e.g., oncology, neurodegenerative diseases).
• Diversified Risk Profile: Investing in a company with multiple Aspirin-related IP assets across different therapeutic areas can diversify risk.
• Long-Term Value Creation: Successful development of patent-protected novel formulations or new indications can lead to significant, long-term market exclusivity and value creation, far beyond generic competition.
• Partnership Opportunities: Smaller biotech or specialty pharma companies with promising Aspirin IP may seek partnerships or acquisitions from larger pharmaceutical firms looking to expand their portfolios.
• Regulatory Pathway: Navigating regulatory approval for new indications or complex formulations is a significant hurdle and cost.

Recommendation: Investments in Aspirin should focus on companies with a strong pipeline of patent-protected innovations, including novel formulations and the repositioning of Aspirin for new indications. Due diligence should rigorously assess the strength of IP, the clinical evidence for new uses, and the regulatory pathway.

KEY TAKEAWAYS

• Carisoprodol's intellectual property protection has long expired, leading to a mature, price-sensitive generic market. Its abuse potential imposes significant regulatory hurdles, limiting opportunities for novel IP-driven growth. Investment is primarily in operational efficiency.
• Aspirin, while also off-patent for its base molecule, presents substantial opportunities for investment in novel formulations, combination therapies, and the repositioning of the drug for new indications, particularly in oncology and neurodegenerative diseases.
• Investment strategies for Carisoprodol should focus on cost-efficiency and distribution, offering limited upside.
• Investment strategies for Aspirin should target companies with robust patent portfolios in innovative formulations, combination products, and emerging therapeutic areas, offering significant long-term growth potential.

FREQUENTLY ASKED QUESTIONS

1. Are there any active patents on Carisoprodol itself that could be acquired for market exclusivity? No, patents on the original Carisoprodol molecule and its basic synthesis have long expired. Any patent activity would likely be related to novel manufacturing processes or very specific, limited formulations that do not confer broad market exclusivity.

2. What is the primary differentiator for branded Aspirin products in the current market? Branded Aspirin products differentiate themselves primarily through brand recognition, consumer trust, and established marketing channels. Some may also offer specific formulations with perceived advantages, such as improved ease of swallowing or faster dissolution. However, these do not typically involve patent protection on the Aspirin molecule itself.

3. How significant is the abuse potential of Carisoprodol and how does it impact its market? Carisoprodol is a Schedule IV controlled substance in the U.S. due to its potential for abuse and dependence. This classification leads to stricter prescribing, dispensing, and manufacturing regulations, limiting its widespread use and discouraging new product development beyond generic versions.

4. What are the most promising therapeutic areas for Aspirin repositioning that could lead to new IP? The most promising areas include oncology, where Aspirin is being investigated for cancer prevention and as an adjuvant therapy, and neurodegenerative diseases, such as Alzheimer's and Parkinson's, where its anti-inflammatory and potential anti-amyloid properties are being explored.

5. Are there significant regulatory barriers to developing new combination therapies involving Aspirin? Developing new combination therapies requires navigating rigorous regulatory pathways, including demonstrating safety and efficacy for the combination product. For fixed-dose combinations, specific studies are needed to justify the co-administration of the APIs. However, the extensive safety data for Aspirin can be advantageous in such development.

CITATIONS

[1] Chan, A. T. S. (2019). Aspirin and cancer. The New England Journal of Medicine, 381(7), 647–654. https://doi.org/10.1056/nejmra1808364

[2] D'Arcy, P. F. (1994). Salicylate toxicity and children. The Pharmaceutical Journal, 253(6564), 354–356. (Note: This reference discusses salicylate toxicity, implying a need for improved formulations for tolerability. Specific studies on Aspirin Lysine would be needed for direct citation of its formulation advantage.)